The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection

Surgical Infections

Volumn 5, Issue 3, 2004, Pages 269-280

  Barie, Philip S ^a,e   Rotstein, Ori D ^b   Dellinger, E Patchen ^c   Grasela, Thaddeus H ^d   Walawander, Cynthia A ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Pharmaceutical Outcomes Res Inc   (United States)

^e Department of Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CILASTATIN PLUS IMIPENEM; METRONIDAZOLE; PLACEBO;

ABDOMINAL INFECTION; ARTICLE; CANADA; CLINICAL STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZATION; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; SURGICAL TECHNIQUE; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

EID: 7744238299     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2004.5.269     Document Type: Article

References (39)

1. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect 2002;3:161-173.
2. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect 2002;3:175-233.
3. Franklin GA. The driving force in hospital formularies: Economics versus efficacy. Am J Surg 2003;186: 55S-60S.
4. Thornsberry C, Yee YC. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am J Med 1996;100(suppl 6A):265-385.
5. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole to imipenem/cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 1997;132:1294-1302.
6. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829.
7. Solomkin JS, Hemsell DL, Sweet R, et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of intra-abdominal and pelvic infections, Clin Infect Dis 1992;15(suppl 1):S33-S42.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
9. de Lissovoy G, Elixhauser A, Luce B, et al. Cost analysis of imipenem-cilastatin versus clindamycin with tobramycin in the treatment of acute intraabdominal infection. Pharmacoeconomics 1993;4:203-214.
10. 1996 Red Book. Montvale, NJ: Medical Economics Data Production Co., 1996.
11. Granata AV, Hillman AL. Competing practice guidelines: Using cost-effectiveness analysis to make optimal decisions. Ann Intern Med 1998;128:56-63.
12. Neumann PI, Hermann RC, Berenbaum PA, Weinstein MC. Methods of cost effectiveness analysis in the assessment of new drugs for Alzheimer's disease. Psychiatr Serv 1997;48:1440-1444.
13. Elliott SL, Harris AH. The methodology of cost-effectiveness analysis: Avoiding common pitfalls. Med J Aust 1997;166:636-639.
14. Birkmeyer JD, Weleh HG. A reader's guide to surgieal decision analysis. J Am Coll Surg 1997;184;589-595.
15. Birkmeyer JD, O'Connor-Birkmeyer N. Decision analysis in surgery. Surgery 1996;120:7-15.
16. Russell LB, Gold MR, Siegel JE, et al. Panel on cost-effectiveness in health and medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-1177.
17. Weinstein MC, Siegel JE, Gold MR, et al. Panel on cost-effectiveness in health and medicine. Recommendation of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
18. Seigel JE, Weinstein MC, Russell LB, Gold MR. Panel on cost effectiveness in health and medicine. Recommendation for reporting cost-effectiveness analyses. JAMA 1996;276:1339-1341.
19. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996;223:303-315.
20. Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections. Pharmacoeconomics 1999;16:551-561.
21. Brasel KJ, Borgstrom DC, Weigelt JA. Cost-utility analysis of contaminated appendectomy wounds. J Am Coll Surg 1997;184:23-30.
22. Kuntz KM, Kent KC. Is carotid endarteretomy cost-effective? An analysis of symptomatic and asymptomatic patients. Circulation 1996;94:94-98.
23. Caviness AC, Cantor SB, Allen CH, Ward MA. A cost-effectiveness analysis of bacterial endocarditis prophylaxis for febrile children who have cardiac lesions and undergo urinary catheterization in the emergency department. Pediatrics 2004;113:1291-1296.
24. Jasmer RM, Snyder DC, Saukkonen JJ, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis 2004;38:363-369.
25. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-43.
26. Ost DE, Hall CS, Joseph G, et al. Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 2003; 168:1060-1067.
27. Vinken AG, Li JZ, Balan DA, et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in U.S. hospitals. Am J Ther 2003;10:264-274.
28. Fabian TC, Boucher BA, Croce MC. Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury. Pharmacotherapy 1996;16:951-957.
29. Kreter B. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin + aminoglycoside combination therapy for treatment of serious lower respiratory, intraabdominal, gynecologic, and urinary tract infections Clin Ther 1992;14:110-121.
30. Nystrom PO, Bax R, Dellinger EP, et al. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. World J Surg 1990;14:148-158.
31. Bohnen JM, Mustard RA, Oxholm SE, Schouten BD. APACHE II score and abdominal sepsis. A prospective study. Arch Surg 1988;123:225-229.
32. Levison MA, Ziegler D. Correlation of APACHE II score, drainage technique and outcome in postoperative intra-abdominal abscess. Surg Gynecol Obstet 1991:172:89-94.
33. Christou NV, Barie PS, Dellinger EP, et al. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg 1993;128:193-199.
34. Barie PS, Hydo LJ, Fischer E. Development of multiple organ dysfunction syndrome in critically ill patients with perforated viscus. Predictive value of APACHE severity scoring. Arch Surg 1996;131:37-43.
35. Pacelli F, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996;131:641-645.
36. Ohmann C, Yang Q, Hau T, et al. Prognostic modelling in peritonitis. Eur J Surg 1997;163:53-60.
37. Jolicoeur LM, Jones-Grizzle AJ, Boyer G. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992;49:1741-1747.
38. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results or a multicenter trial comparing imipenem/ cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990;212:581-591.
39. Beam TR, Gilbert DN, Kunin CM. General guidelines for clinical evaluation of anti-infective drug products. Clin Infect Dis 1992;15(suppl 1):S5-S41.